臨床検査57巻12号

2013年11月発行

今月の特集1 前立腺癌マーカー

proPSA測定とその意義

著者： 伊藤一人¹

所属機関： ¹群馬大学大学院医学系研究科泌尿器科学

ページ範囲：P.1448 - P.1456

■前立腺癌組織ではhuman kallikrein 2濃度の低下によりproPSAから活性型PSAへ変換が阻害されることでproPSAが線腔内に蓄積し，微小血管浸潤によりproPSAの血中逸脱が増加する可能性が示唆されている．

■［-2］proPSAのモノクローナル抗体を用いた免疫組織染色で，前立腺癌組織では良性腺管と比べ強く腺組織が染色され，［-2］proPSAはより癌特異的なマーカーとして期待が持てる．

■［-2］proPSA関連インデックスは既存の腫瘍マーカーと比べ優れた癌診断精度を示し，さらに癌の組織学的悪性度や腫瘍体積と有意な相関性が認められた．

参考文献

1）雑賀公美子，松田智大，祖父江友孝：日本のがん罹患の将来推計．がん・統計白書2012―データに基づくがん対策のために（祖父江友孝，片野田耕太，味木和喜子，他編），篠原出版新社，pp63-81，2012

2）Schröder FH, Hugosson J, Roobol MJ, et al：Prostate-cancer mortality at 11 years of follow-up. N Engl J Med　366：981-990，2012

3）Hugosson J, Carlsson S, Aus G, et al：Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol　11：725-732，2010

4）Chan TY, Mikolajczyk SD, Lecksell K, et al：Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology　62：177-181，2003

5）Igawa T, Takehara T, Onita T, et al：Analysis of short-term measurement stability of [-2]pro-PSA in whole-blood and serum samples from Japanese males. J Clinical Laboratory Analysis, in press

6）Catalona WJ, Smith DS, Wolfert RL, et al：Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA　274：1214-1220，1995

7）Prestigiacomo AF, Lilja H, Pettersson K, et al：A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates : the best case scenario. J Urol　156(2 Pt 1)：350-354，1996

8）Partin AW, Catalona WJ, Southwick PC, et al：Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology　48(6A Suppl)：55-61，1996

9）Le BV, Griffin CR, Loeb S, et al：[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol　183：1355-1359，2010

10）Catalona WJ, Partin AW, Sanda MG, et al：A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0ng/ml prostate specific antigen range. J Urol　185：1650-1655，2011

11）Sokoll LJ, Sanda MG, Feng Z, et al：A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA : improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev　19：1193-1200，2010

12）Ito K, Miyakubo M, Sekine Y, et al：Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0ng/mL range. World J Urol　31：305-311，2013

13）Guazzoni G, Lazzeri M, Nava L, et al：Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol　61：455-466，2012

14）Tosoian JJ, Loeb S, Feng Z, et al：Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol　188：1131-1136，2012